GlaxoSmithKline PLC (GSK)

41.03
0.03 0.07
NYSE : Health Care
Prev Close 41.06
Open 40.97
Day Low/High 40.94 / 41.24
52 Wk Low/High 37.20 / 45.58
Volume 3.78M
Avg Volume 3.77M
Exchange NYSE
Shares Outstanding 2.44B
Market Cap 100.71B
EPS 0.50
P/E Ratio 23.76
Div & Yield 2.30 (5.60%)

Latest News

Gilead and 'Good News' Make A Rare, Joint Appearance at HIV Conference

Gilead and 'Good News' Make A Rare, Joint Appearance at HIV Conference

With sales of its hepatitis C drugs falling and an oncology pipeline that has largely disappointed, bictegravir is vitally important for Gilead to defend and grow its dominant HIV franchise.

3 Stocks Poised for Gains Under the Donald Trump Era

3 Stocks Poised for Gains Under the Donald Trump Era

With stocks at record highs, there are still buying opportunities, but investors should be selective.

Glaxo Beats Expectations for Fourth-Quarter Earnings; Shares Fall on Advair Concerns

Glaxo Beats Expectations for Fourth-Quarter Earnings; Shares Fall on Advair Concerns

GlaxoSmithKline beat analysts' expectations for fourth-quarter sales and earnings Wednesday but warned of a significant hit this year from anticipated generic competition to its Advair asthma treatment.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

U.S. stock futures are rising Wednesday while European and Asian shares trade higher despite a continued dip in oil prices.

Earnings Preview: GlaxoSmithKline Likely to See Currency Boost; Advair Sales in Focus

Earnings Preview: GlaxoSmithKline Likely to See Currency Boost; Advair Sales in Focus

GlaxoSmithKline reports fourth-quarter earnings Wednesday, with investors looking for guidance on the fate of its key Advair drug and the recent pace of organic growth for new products sales.

Brexit Already Having a Negative Impact, Business Leaders Say

Brexit Already Having a Negative Impact, Business Leaders Say

The U.K.'s top business leaders have painted a pessimistic view of Brexit, with more than half of respondents in a survey saying that it is already having a negative impact.

Week Ahead: Trump Takes the Wheel as Fourth-Quarter Earnings Power On

Week Ahead: Trump Takes the Wheel as Fourth-Quarter Earnings Power On

Wall Street should expect the unexpected in week three of Trump's America.

An Ominous Pattern Emerges

Don't get stranded on this island reversal.

Now That Dow Has Hit 20,000, GM and Nike Are Hot Stocks

Now That Dow Has Hit 20,000, GM and Nike Are Hot Stocks

Some of Wall Street's biggest stocks are teetering on the edge of breakout territory this week. Here are five of them.

GM, Nike, Microsoft Are Hot Now That Dow Has Hit 20,000

GM, Nike, Microsoft Are Hot Now That Dow Has Hit 20,000

Some of Wall Street's biggest stocks are teetering on the edge of breakout territory this week. Here are five of them.

Bullish and Bearish Reversals in the Market

Bullish and Bearish Reversals in the Market

These companies show signs of a change of direction.

Hey, What About the Transports?

They were red today and no one seems to care.

'Mad Money' Lightning Round: Southwestern Energy, UnitedHealth, Celgene and More

'Mad Money' Lightning Round: Southwestern Energy, UnitedHealth, Celgene and More

Jim Cramer favors UnitedHealth over Cerner, and U.S. Concrete more than Cemex.

Jim Cramer's 'Mad Money' Recap: Don't Worry About a Little Market Detour

Jim Cramer's 'Mad Money' Recap: Don't Worry About a Little Market Detour

Get used to some down days, says Jim Cramer, but don't lose sight of the success for financial stocks.

GSK Starts Phase III Study Of Once-Daily Closed Triple Combination Therapy FF/UMEC/VI In Patients With Asthma

GSK Starts Phase III Study Of Once-Daily Closed Triple Combination Therapy FF/UMEC/VI In Patients With Asthma

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the start of a phase III study investigating the effects of once-daily closed triple combination therapy fluticasone...

How You Can Profit as the Market for COPD Drugs Grows

How You Can Profit as the Market for COPD Drugs Grows

Hundreds of millions of people worldwide suffer from chronic respiratory disease. Here's how investors can profit from the companies making strides in treating COPD.

Pfizer Takes $106 Million Fine From U.K. for Price Hike of Epilepsy Drug

Pfizer Takes $106 Million Fine From U.K. for Price Hike of Epilepsy Drug

The U.K. regulator takes exception to the sale of Epanutin to Flynn Pharma, which drove the price up by 2,600%.

How to Buy GlaxoSmithKline at a 15% Discount

How to Buy GlaxoSmithKline at a 15% Discount

Investors seeking more returns can not only get some yield, but also healthy dividends from buying options on stocks. Those who are seeking additional opportunities can purchase GlaxoSmithKline (GSK),

GSK Files Regulatory Submission In European Union For Once-Daily Closed Triple Combination Therapy FF/UMEC/VI For Patients With COPD

GSK Files Regulatory Submission In European Union For Once-Daily Closed Triple Combination Therapy FF/UMEC/VI For Patients With COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by GSK of a regulatory submission with the European Medicines Agency for once-daily, closed triple combination therapy...

Relvar® Ellipta® 100/25 Mcg Gains Approval In Japan For Use In Patients With COPD

Relvar® Ellipta® 100/25 Mcg Gains Approval In Japan For Use In Patients With COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Relvar ® Ellipta ® (fluticasone furoate /...

10 Undervalued High-Yield Dividend Stocks Worth Buying Today

10 Undervalued High-Yield Dividend Stocks Worth Buying Today

Each dividend stock scores well for safety and has a historically high dividend yield.

2 Excellent Dividend-Paying Drug Stocks to Add to Your Portfolio

2 Excellent Dividend-Paying Drug Stocks to Add to Your Portfolio

These two pharmaceutical stocks offer great yields.

GSK Files Regulatory Submission In US For Once-Daily Closed Triple Combination Therapy FF/UMEC/VI For Patients With COPD

GSK Files Regulatory Submission In US For Once-Daily Closed Triple Combination Therapy FF/UMEC/VI For Patients With COPD

GlaxoSmithKline plc (LSE/NYSE: GSK) and Innoviva, Inc. (NASDAQ: INVA) today announced the filing by GSK of a regulatory submission with the US Food and Drug Administration for the once-daily, closed triple combination...

Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit

Here's Which Pharma Giants Might Want to Buy Pfizer's Consumer Health Unit

A sale or spinoff of this business will likely get the attention of competitors that want to increase their over-the-counter product units.

Tracing Benjamin Graham's Descendants

Tracing Benjamin Graham's Descendants

Firms' 13F filings show how they've followed in the footsteps of the father of value investing.

Here Are 3 Ways to Play the Growing Market for Vaccines Right Now

Here Are 3 Ways to Play the Growing Market for Vaccines Right Now

This market is exploding in the U.S., presenting better investment opportunities than other types of therapies.

Donald Trump Election Victory Boosts Some Stocks and Sectors

Donald Trump Election Victory Boosts Some Stocks and Sectors

As we all know, the stock market and the economy abhor uncertainty.

The Likely Market Impact of President Trump

As we all know, the stock market and the economy abhor uncertainty.